CellaVision Overview

  • Founded
  • 1994
Founded
  • Status
  • Public
  • Employees
  • 180
Employees
  • Stock Symbol
  • CEVI
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $40.96
  • (As of Thursday Closing)

CellaVision General Information

Description

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China and Japan. The company derives the majority of its revenue from the sale of analyzers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Devices and Supplies
Other Industries
Other Healthcare Technology Systems
Stock Exchange
STO
Primary Office
  • Ideon Science Park
  • Scheelevägen 19
  • 223 70 Lund
  • Sweden
+46 0286-44 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CellaVision Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$40.96 $41.08 $28.09 - $45.37 $977M 23.9M 22.6K $0.46

CellaVision Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 888,982 898,309 800,600 493,994
Revenue 52,917 51,131 48,821 41,927
EBITDA 17,891 15,878 15,937 13,681
Net Income 10,977 9,705 10,485 10,193
Total Assets 80,835 81,436 68,635 41,472
Total Debt 19,272 16,186 18,578 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CellaVision Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CellaVision‘s full profile, request access.

Request a free trial

CellaVision Executive Team (11)

Name Title Board Seat Contact Info
Zlatko Rihter Chief Executive Officer
Magnus Blixt Chief Financial Officer
Hans-Inge Bengtsson Director, Scientific Affairs
Ron Hagner Vice President of Business Development & Scientific Affairs
Peter Wilson Vice President of Global Marketing
You’re viewing 5 of 11 executive team members. Get the full list »

CellaVision Board Members (8)

Name Representing Role Since
Anna Bernsten Self Board Member 000 0000
Christer Fåhraeus Ph.D Self Founder & Board Member 000 0000
Niklas Prager Self Board Member 000 0000
Roger Johanson Self Board Member 000 0000
Sven-Åke Henningsson Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

CellaVision Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CellaVision Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CellaVision‘s full profile, request access.

Request a free trial

CellaVision Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 00000000000 01-Oct-2019 000000000000000000 000.00 Medical Supplies 000000 000000
Clear Lake Medical Foundation 23-Jun-2014 Merger/Acquisition 000 Other Healthcare Technology Systems 000000 0å00000000
To view CellaVision’s complete acquisitions history, request access »

CellaVision Subsidiaries (1)

Company Name Industry Location Founded
000 00000000000 Medical Supplies Martillac, France 0000
To view CellaVision’s complete subsidiaries history, request access »